Novo Nordisk battling $3.9 billion TP adjustment on transfer of biopharmaceutical division
Denmark’s largest listed company, Novo Nordisk, has been hit with transfer pricing adjustments of DKK 22 billion ($3.95 billion) by the Danish tax authority (SKAT) resulting in an increased tax bill of DKK 5.5 billion.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
